RESULTS OF TREATMENT WITH COMBINED HORMONAL AND PROGESTOGENIC HORMONAL CONTRACEPTIVES IN WOMEN WITH AUTOIMMUNE THYROIDITIS AT THE FERTILE AGE

Hajizadeh A. E.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. The urgency of the problem. Conclusions in literature about the prevalence of autoimmune diseases of the thyroid gland, including autoimmune thyroiditis and its potential impact on infertility is very contradictory and continuing of studies in this sphere is considered as important. The purpose of the study is to study the effect of 12-month combined hormonal and progestogenic hormonal treatments among women with autoimmune thyroiditis of reproductive age on the thyroid and reproductive system, the level of specific anti-TPO and anti-thyroglobulin antibodies. Object and methods of the research. The research materials consists of medical records of 48 patients who received complex treatment for autoimmune thyroiditis and infertility. Patients were divided into four subgroups for this purpose. 12 patients receiving combined oral contraceptives (COCs) and thyroxine were in the I subgroup, 12 patients receiving only combined oral contraceptives (COCs) were in II, 12 patients receiving desogestrel and thyroxine were in III subgroup, and 12 patients receiving only desogestrel were in IV subgroup. The complexexamination includes general-clinical, instrumental, laboratory methods and special examination methods. Selected examination methods were adequate for intended purposes and objectives.The level of anti-thyroglobulin autoantibodies (anti-TG antibodies) and anti-thyroid peroxidase antibodies (anti-TPO antibodies) was studied by the enzyme-linked immunosorbent method. The results of the study and their discussion. In patients of the first subgroup with autoimmune thyroiditis taking COCs against the background of thyroxine use, after 12 months there was a significant decrease in blood TSH from 1.9±0.1 mIU/L to 1.4±0.2 mIU/L (p<0.05). The change in TSH levels 12 months after taking COC among patients in subgroup II who were not prescribed thyroxine treatment was inaccurate. Patients with autoimmune thyroiditis of subgroup III receiving progestogen desogestrel with a dose of 50-75 mcg of thyroxine showed a significant decrease in TSH in blood levels after 12 months (p<0.05). In fertile older women with autoimmune thyroiditis, 12- month use of micro- and low-dose combined oral contraceptives resulted in a significant decrease in plasma levels of anti-thyroid peroxidase and anti-thyroglobulin antibodies (p<0.05). Hestagen desogestrel’s use for 12 months resulted in a significant reduction in plasma-only antibodies to thyroid peroxidase.

autoimmune thyroiditis, infertility, hypothyroidism, treatment of infertility, treatment of hypothyroidism.

1. Perminova SG. Patologija shhitovidnoj zhelezy u zhenshhin s besplodiem. Klin. i jeksper. tireoidol. 2011;7(4):44-50. [in Russiаn].
2. Nikonova LV, Tishkovskij SV. Zabolevanija shhitovidnoj zhelezy i beremennost’. Autoimmunnyj tireoidit, gipotireoz, tireotoksikoz pri beremennosti: sovremennye principy diagnostiki i lechenija. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2016;1:82-87. [in Russiаn].
3. Junusov AA, Zaharov GA. Ocenka lechenija pri patologii shhitovidnoj zhelezy i reproduktivnoj sistemy u zhenshhin. Vestnik KRSU. 2014;14(4):171-174. [in Russiаn].
4. Perminova SG, Ibragimova MH, Nazarenko TA. Besplodie i gipotireoz Problemy zhenskogo zdorov’ja. 2008;2(3):65-75. [in Russiаn].
5. Mihajlova SV, Zykova TA. Autoimmunnye bolezni shhitovidnoj zhelezy i reproduktivnye narushenija u zhenshhin. Sibirskij medicinskij zhurnal. 2013;8:26-31. [in Russiаn].
6. Karaca N, Akpak YK. Thyroid disorders and fertility. International Journal of Research in Medical Sciences. 2015;3(6):1299-1304.
7. Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;285:853-6

«Bulletin of problems biology and medicine» Issue 2 (160), 2021 year, 81-85 pages, index UDK 616.441-002-097-055.2:615.357; 618.179-084

10.29254/2077-4214-2021-2-160-81-85